QNCX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
QNCX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Quince Therapeutics has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.GuruFocus does not calculate Quince Therapeutics's interest coverage with the available data. As of today, Quince Therapeutics's Altman Z-Score is 0.00.
For the Biotechnology subindustry, Quince Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Quince Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Quince Therapeutics's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Quince Therapeutics's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-8.34 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13.75 Mil.
Quince Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is
GuruFocus does not calculate Quince Therapeutics's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Quince Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Quince Therapeutics's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
Debt to Revenue Ratio | = | Total Debt (Q: Dec. 2023 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.064 | + | 13.75) | / | 0 | |
= | N/A |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Quince Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quince Therapeutics (NAS:QNCX) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Quince Therapeutics has the Financial Strength Rank of 6.
Thank you for viewing the detailed overview of Quince Therapeutics's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
David Lamond | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Guenter Janhofer | officer: Chief Scientific Officer | 601 GATEWAY BOULEVARD, SUITE 1250, SOUTH SAN FRANCISCO CA 94080 |
Luca Benatti | director | C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011 |
Charles S. Ryan | officer: President | C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790 |
Dirk Thye | director, officer: Chief Executive Officer | 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Brendan Hannah | officer: Chief Business Officer | 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Margaret Mcloughlin | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Ted Monohon | officer: Chief Accounting Officer | C/O FANTEX, INC., 330 TOWNSEND ST., SUITE 234, SAN FRANCISCO CA 94107 |
June Bray | director | C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511 |
Caryn Gordon Mcdowell | officer: Chief Legal & Adm. Officer | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Karen L. Smith | officer: Chief Medical Officer | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Philip S Low | director | 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906 |
Marwan Sabbagh | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Stephen S. Dominy | director, officer: Chief Scientific Officer | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94105 |
Christopher P. Lowe | officer: Chief Financial Officer | 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 06-06-2023
By GuruFocusNews GuruFocusNews • 04-27-2022
By Business Wire Business Wire • 06-21-2022
By Business Wire • 07-24-2023
By PRNewswire PRNewswire • 04-25-2022
By GuruFocusNews GuruFocusNews • 04-21-2022
By ACCESSWIRE ACCESSWIRE • 03-21-2023
By Business Wire Business Wire • 05-20-2022
By Business Wire Business Wire • 07-27-2022
By Business Wire Business Wire • 07-27-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.